Credit Suisse Group restated their hold rating on shares of Eli Lilly and (NYSE:LLY) in a report released on Wednesday morning.

LLY has been the subject of several other reports. BMO Capital Markets reiterated a sell rating and set a $71.00 price target on shares of Eli Lilly and in a research report on Thursday, September 28th. Cowen reiterated a buy rating and set a $95.00 price target on shares of Eli Lilly and in a research report on Wednesday, October 4th. Jefferies Group reiterated a buy rating and set a $89.00 price target (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. BidaskClub cut Eli Lilly and from a hold rating to a sell rating in a research report on Tuesday, August 22nd. Finally, Piper Jaffray Companies reiterated a buy rating and set a $105.00 price target on shares of Eli Lilly and in a research report on Friday, October 13th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the stock. Eli Lilly and presently has an average rating of Hold and a consensus price target of $90.25.

Eli Lilly and (NYSE:LLY) opened at $86.54 on Wednesday. Eli Lilly and has a 12 month low of $71.76 and a 12 month high of $89.09. The stock has a market capitalization of $95,321.79, a PE ratio of 21.17, a PEG ratio of 1.76 and a beta of 0.35. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period last year, the business posted $0.88 earnings per share. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. research analysts anticipate that Eli Lilly and will post 4.22 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be given a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.60%. Eli Lilly and’s payout ratio is 98.58%.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total value of $17,796,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jeffrey N. Simmons sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $86.46, for a total value of $1,080,750.00. Following the completion of the sale, the senior vice president now owns 124,522 shares of the company’s stock, valued at $10,766,172.12. The disclosure for this sale can be found here. Insiders sold 651,088 shares of company stock valued at $56,439,586 over the last 90 days. Company insiders own 0.20% of the company’s stock.

Several large investors have recently modified their holdings of the company. Accredited Investors Inc. boosted its stake in shares of Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after acquiring an additional 14 shares during the last quarter. Northwest Quadrant Wealth Management LLC boosted its stake in shares of Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after acquiring an additional 19 shares during the last quarter. Oakworth Capital Inc. boosted its stake in shares of Eli Lilly and by 0.3% in the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after acquiring an additional 20 shares during the last quarter. Sfmg LLC boosted its stake in shares of Eli Lilly and by 0.5% in the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after acquiring an additional 20 shares during the last quarter. Finally, Jackson Grant Investment Advisers Inc. boosted its stake in shares of Eli Lilly and by 0.7% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after acquiring an additional 24 shares during the last quarter. 76.42% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/17/eli-lilly-and-lly-rating-reiterated-by-credit-suisse-group.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related stocks with our FREE daily email newsletter.